Holen Sie sich die Stockscreener-App
2.84
10.51%
0.27
Vorhandelsmarkt:
2.80
-0.04
-1.41%
Schlusskurs vom Vortag:
$2.57
Offen:
$2.51
24-Stunden-Volumen:
4.68M
Relative Volume:
1.74
Marktkapitalisierung:
$961.84M
Einnahmen:
$796.85M
Nettoeinkommen (Verlust:
$30.44M
KGV:
33.73
EPS:
0.0842
Netto-Cashflow:
$93.88M
1W Leistung:
+20.34%
1M Leistung:
+38.54%
6M Leistung:
-8.68%
1J Leistung:
-25.07%
1-Tages-Spanne:
$2.47
$2.84
1-Wochen-Bereich:
$2.355
$2.84
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, DOCS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.84 | 961.84M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
168.25 | 27.46B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
52.94 | 10.27B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
49.47 | 8.88B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
83.99 | 7.10B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
26.03 | 4.81B | 637.78M | 239.40M | 307.21M | 1.1909 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS ; Offers Guidance - StreetInsider
Number of shareholders of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - Yahoo Finance
GoodRx (NASDAQ:GDRX) Beats Q1 CY2026 Sales Expectations - Barchart.com
GoodRx Holdings Q1 Adjusted Earnings, Revenue Fall - marketscreener.com
GoodRx (NASDAQ: GDRX) Q1 2026 shifts from Rx volume to Pharma Direct growth - Stock Titan
GoodRx Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GoodRx Reports First Quarter 2026 Results - Business Wire
3 Promising Penny Stocks With Market Caps Up To $900M - simplywall.st
GoodRx Holdings Inc expected to post earnings of 7 cents a shareEarnings Preview - TradingView
GDRX SEC FilingsGoodrx Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
GoodRx (NASDAQ: GDRX) CAO Thomas Chan reports stock, options and RSUs - Stock Titan
Why GoodRx (GDRX) Stock Is Trading Up Today - Barchart.com
GoodRx offers oral semaglutide starting at $149 per month By Investing.com - Investing.com India
GoodRx expands offerings to now include Ozempic® pill for type 2 diabetes patients - marketscreener.com
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients - Quantisnow
A new Ozempic pill now starts at $149 a month through GoodRx - Stock Titan
GDRX Forecast, Price Target & Analyst Ratings | GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) - ChartMill
[ARS] GoodRx Holdings, Inc. SEC Filing - Stock Titan
Executive pay, auditor change headline GoodRx (NASDAQ: GDRX) 2026 vote - Stock Titan
What's Going On With GoodRx Stock Thursday? - Sahm
GDRX vs. HQY: Which Stock Is the Better Value Option? - MSN
GoodRx (GDRX) Q2 2024 earnings summary - Quartr
GoodRx won't be participating with TrumpRx: report - MSN
What's going on with GoodRx stock Thursday? - MSN
GoodRx Holdings, Inc. Appoints New Chief Accounting Officer and Files Form 8-K with SEC - Minichart
GoodRx appoints Thomas Chan as chief accounting officer By Investing.com - Investing.com India
GoodRx Names Thomas Chan Chief Accounting Officer - TipRanks
GoodRx appoints Thomas Chan as chief accounting officer - Investing.com
GoodRx names Thomas Chan as Chief Accounting Officer - TradingView
GoodRx (NASDAQ: GDRX) appoints Thomas Chan as new Chief Accounting Officer - Stock Titan
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy? - The Globe and Mail
GDRX GoodRx Holdings shares climb 4.41 percent after Q4 2025 results despite a minor EPS miss against analyst expectations.Social Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GDRX (GoodRx Holdings Inc.) drops 3.4% today after Q4 2025 EPS narrowly falls short of analyst expectations.Risk Event - Xã Thanh Hà
GoodRx Holdings (GDRX) Sector Leadership | Q4 2025: EPS Misses EstimatesSector Outperform - Cổng thông tin điện tử tỉnh Tây Ninh
Healthcare Technology Stocks Q4 Recap: Benchmarking GoodRx (NASDAQ:GDRX) - Barchart.com
GoodRx Holdings (GDRX) Stock Municipal Bond (Slight Rise) 2026-04-20Crowd Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GoodRx Holdings (GDRX) Stock Trade Ticket (-3.40%) 2026-04-18Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call - 01net
GoodRx rallies as Wegovy HD rollout targets self-pay market - MSN
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Goodrx Holdings Inc-Aktie (GDRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
1.41%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):